Proactive - Interviews for investors

Jubilee Metals Group (AIM:JLP, JSE:JBL, OTC:JUBPF) CEO Leon Coetzer shares insights into the company's positive performance in the first half of the year in an interview with Proactive's Stephen Gunnion.

Despite pressure on platinum group metals (PGM) prices, Jubilee Metals experienced a robust operational and financial performance. Coetzer attributed this to a strategic shift towards focusing on chrome and copper production in South Africa and Zambia, respectively. The company has seen significant growth in operational output and an increase in the margin per tonne of chrome. Copper production is also on the rise, with the Roan concentrator upgrade expected to significantly boost copper output.

Coetzer said Jubilee Metals remained profitable due to its diversified portfolio in critical metals and is well-positioned to benefit from any recovery in PGM prices.

Coetzer highlighted a 47% increase in copper cathode and concentrate production over the half-year and discussed the impact of the Roan concentrator, which is expected to more than double current production. Additionally, a partnership with International Resources Holding (IRH) from Abu Dhabi aims to further expand copper production in Zambia by leveraging the company's processing capabilities to target underutilized resources.

The company's balance sheet is healthy, bolstered by a £13 million oversubscribed capital raise in January.

Coetzer noted that Jubilee Metals' operations in South Africa are self-funding and cash flow positive, allowing for reinvestment into the company's growth. The strategic use of modular plant rollouts in Zambia is expected to follow a similar financially positive trajectory.

#JubileeMetals #LeonCoetzer #Mining #ChromeProduction #CopperExpansion #FinancialPerformance #StrategicGrowth #SouthAfricaMining #ZambiaMining #MetalDiversification #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblastoma patients.

Connelly explained that glioblastoma, the most common malignant brain tumour, significantly impacts brain function, highlighting the importance of clinical trials to improve patient quality of life.

The trial, opened nearly two years ago, investigates gallium maltolate, an oral medication showing promise in preclinical studies and animal models for efficacy against tumour cells. This phase focuses on drug tolerance, with patients reporting ease of use compared to traditional treatments and the ability to maintain normal daily activities.

An expanded access programme (EAP), also known as compassionate use, has been launched by IA-AI subsidiary Imaging Biometric to allow wider access to gallium maltolate across the country, benefiting patients unable to travel to the Medical College of Wisconsin. The EAP, approved by the FDA, aims to collect additional safety and toxicity data, contributing to the trial's findings and supporting the progression towards a phase two clinical trial.

The next milestone, by the end of 2024, involves concluding the phase one trial, determining the maximum tolerated dose, and preparing for the phase two trial slated for 2025, focusing on safety and beginning to evaluate efficacy.

#IQAI #ClinicalTrial #Glioblastoma #GalliumMaltolate #PhaseOneTrial #MedicalCollegeOfWisconsin #CancerResearch #ExpandedAccessProgram #FDAApproved #NeuroOncology #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ondo InsurTech PLC (LSE:ONDO) CEO Craig Foster joins Proactive's Stephen Gunnion with news the company has partnered with South West Water to deploy 6,000 LeakBots in a water-stressed region in the UK to reduce leaks, marking its third collaboration with a UK water company.

This initiative is part of a broader effort to address water scarcity in the UK, exacerbated by climate change and population growth. Foster highlighted that 8% of UK toilets leak, wasting significant amounts of water daily. Ondo InsurTech's LeakBot solution allows homeowners to easily install a device that detects leaks, enabling timely repairs.

In the US, Ondo InsurTech is expanding its footprint, inking a deal with Selective Insurance, the US property and casualty group, which will offer its LeakBot, a self-install leak detection unit, to policyholders.

The company has now signed agreements with four major insurers in the past nine months, including a significant partnership with Nationwide. These deals demonstrate the company's growing momentum in the US market, where insurers spend around $16 billion annually on water leak damages.

Foster also mentioned Ondo InsurTech's nomination for the Breakthrough of the Year Award at the 2023 PLC Awards, competing against giants like Rolls Royce. Despite considering its chances slim, Foster sees the nomination as an honour and an indication of the company's innovative impact in addressing water conservation and leak prevention.

#OndoInsurTech #WaterConservation #UKWaterStress #USInsurancePartnerships #LeakPreventionTechnology #SustainableSolutions #ClimateChange #PopulationGrowth #WaterLeakDetection #InnovationInInsurance #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

PharmAust Limited (ASX:PAA) CEO Dr Michael Thurn tells Proactive's Stephen Gunnion that the company had a "pivotal" Pre-Investigational New Drug Application (Pre-IND) meeting with the US Food and Drug Administration (FDA) as it advances the development of monepantel, an approved veterinary drug, for motor neurone disease.

Thurn highlighted the drug's potential in exploiting autophagy properties to treat motor neurone diseases by breaking down toxic protein build-ups, particularly TDP-43 aggregates in neurons.

The company has completed a Phase 1 oncology clinical study for monepantel in humans and is preparing for a pivotal field trial in dogs for B cell lymphoma. A significant milestone is the upcoming end of Phase 1 for its motor neurone disease program, with data expected by the end of February.

Thurn said the FDA's positive feedback indicates the potential for full approval after a 48-week study.

Monepantel's mechanism, inducing autophagy, positions it as a promising treatment for various neurodegenerative diseases beyond motor neurone disease, including Alzheimer's and Parkinson's, suggesting its potential as a blockbuster drug.

#PharmAust #Monepantel #MotorNeuronDisease #Biotechnology #ClinicalTrials #FDAApproval #NeurodegenerativeDiseases #Autophagy #VeterinaryMedicine #HealthcareInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Pantheon International PLC (PIP) has experienced a notably active six-month period, as described by Jie Gong, partner at Pantheon and co-lead manager of PIP.

In an interview with Proactive's Stephen Gunnion, Gong noted that key activities included the advancement of a share buyback programme, where PIP has repurchased £157 million of its own shares out of a planned £200 million for the financial year, achieving a 3.8% net asset value (NAV) accretion. This programme aims to exploit a significant investment opportunity, demonstrate confidence in the portfolio's value, and offer shareholders a chance to sell their stakes on an equitable basis.

Additionally, PIP has reworked its capital structure, notably through refinancing its credit facility last October, to diversify and secure more attractive terms. A private placement of low notes in North America was also oversubscribed, indicating strong investor confidence in PIP's portfolio.

Over the six months, PIP reported a 3% increase in NAV per share amidst a quiet private equity market. Key performance indicators include an 18% growth in revenue and EBITDA across its portfolio, consistent with the five-year average. Realisation activities yielded an average money multiple of 2.5 times cost, slightly below the long-term average but still strong.

The stock market performance of PIP saw an 8% increase over six months and 20% over the calendar year.

Looking ahead to 2024, Gong expresses cautious optimism. Market conditions have improved, with signs of increased activity for exits and a robust valuation environment. The stabilisation of interest rates contributes to this positive outlook, though the future remains uncertain with various factors at play.

#PantheonInternational #PIP #PrivateEquity #ShareBuyback #CapitalStructure #InvestmentPerformance #NAVIncrease #PrivatePlacement #MarketOutlook2024 #FinancialUpdate #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 opened lower as it again struggled to match the record-breaking performances seen on other markets last week.

Wall Street, Frankfurt and Paris have all hit new records while in Tokyo overnight, the Nikkei was closing in on the landmark 40,000 level for the first as its rally continued.

London’s blue-chip index was down 6 at 7,699 in early trades with Bunzl leading the falls. It dropped more than 5% on a downbeat outlook statement with the distribution and consumables giant’s annual results.

Property group Hammerson has sold the Union Square shopping centre in Aberdeen for £111 million as its spate of disposals continues.

Ryanair meanwhile warned that delays to its expected Boeing deliveries might mean price hikes and flight cancellations.

Over the weekend, Warren Buffett’s Berkshire Hathaway produced record profits but the legendary investor suggested the days of bumper returns from his financial vehicle might be passed.

#proactiveinvestors #marketreport #ftse #ftse100 #nikkei #bunzl #hammmerson #unionsquare #Ryanair #boeing #warrenbuffet #berkshirehathaway #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Barton Gold Holdings Ltd (ASX:BGD) managing director and CEO Alexander Scanlon sits down with Proactive’s Jonathan Jackson to discuss the company's strategic direction and aspirations in the gold sector. Scanlon provides an overview of Barton Gold's goals and how it plans to become the largest independent gold producer in South Australia. He looks at the specifics of their projects and explains the company’s potential to spearhead the revival of gold production in the region. He also discusses recent positive findings from Area 191 and 51 at Tunkillia and how these results contribute to the company's outlook. Barton has a strong team behind it, is adept at using technologies aimed at cutting costs and speeding up development and has the ground to make a big impact in the South Australian gold scene.

#ProactiveInvestors #BartonGoldHoldings #ASX #Gold

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lightning Minerals Ltd (ASX:L1M) managing director Alex Biggs joins Jonathan Jackson in the Proactive studio to discuss initial results from its reconnaissance activities at the Dalmas and Hiver lithium projects in Quebec, Canada. The company has analytical results from 32 samples, identifying multiple pegmatites that will direct future exploration efforts. It is now awaiting the summer season in Canada to kick in and is planning its next stage of field activities. Biggs describes the potential of the projects, particularly in relation to its proximity to significant lithium discoveries, including the Corvette project by Patriot Battery Metals and the Adina project by Winsome Resources. Finally, Biggs talks about the plans to come for these projects.

#ProactiveInvestors #LightningMinerals #ASX #Lithium #CriticalMinerals

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Great Boulder Resources Ltd (ASX:GBR) managing director Andrew Paterson sits down with Proactive’s Jonathan Jackson to talk through gold intersections and extended mineralisation at Saltbush prospect. The company has intersected gold over a strike of more than 300 metres along the Ironbark corridor of the Side Well Gold Project in Western Australia. Recent aircore drilling unearthed several gold hits and the company is now starting to fill in the gaps along the corridor. Aircore drilling has extended the known gold mineralisation at Saltbush along strike in both directions and results will be followed up in the next drill campaign starting in March. The company has also identified a new target 400 metres away with extremely high levels of Mulga Bill-style pathfinder elements. Paterson said the company looked to have both styles of mineralisation within the Ironbark corridor target area which is an exciting development.

#ProactiveInvestors #GreatBoulderResources #ASX #Gold #SideWellGoldProject

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Sarytogan Graphite Ltd (ASX:SGA) managing director Sean Gregory sits down with Jonathan Jackson in the Proactive studio to discuss recent results from geotechnical drilling at the Sarytogan graphite deposit in central Kazakhstan. The company reported several significant intercepts of greater than 40% total graphitic carbon (TGC) and two individual assays higher than an “extraordinary” 50% TGC. The eight holes drilled last year, totalled 471.3 metres, with high-grade graphite mineralisation reported in 92% of all metres drilled. Gregory also discusses how these results will contribute to the upcoming pre-feasibility study and provides an update on ongoing battery testing, following successful maiden battery results on Sarytogan uncoated spherical purified graphite (USPG) that delivered superior performance to many Chinese synthetic graphites used in lithium-ion batteries. With the PFS and ongoing drilling to come, there should be no shortage of news flow for the company.

#ProactiveInvestors #SarytoganGraphite #ASX #BatteryMetals #Kazakhstan

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews